MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
September 21 2022 - 8:05AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial
cell-engineering company focused on providing enabling platform
technologies to advance innovative cell-based research, as well as
next-generation cell therapeutic discovery, development and
commercialization, today announced that it has relocated its
headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850,
within Maryland’s I-270 Biotech Corridor. The Company’s new 67,000
square-foot facility significantly increases its in-house
manufacturing capacity, as well as research and process development
lab space. This investment represents a major milestone in
MaxCyte’s growth and its ability to support customers and partners
in their journey through therapeutic development to
commercialization.
“The State of Maryland and Montgomery County
have worked relentlessly over several decades to cultivate a robust
life sciences and biotech community, with MaxCyte playing a
critical role in that development,” said Doug Doerfler,
President and CEO of MaxCyte. “During the past 20 years,
MaxCyte has pioneered cell-engineering technology and is now at the
forefront, driving a new generation of cell-based therapies,
particularly in gene editing and immuno-oncology. As we continue
our work toward transforming patients' lives globally, we remain
committed to fearless innovation and scientific solutions that help
our partners discover and develop life-saving therapeutics through
the application of our unmatched technology platforms paired with
outstanding support and expertise.”
This new facility, with expanded lab and
manufacturing spaces will enable MaxCyte to support the growing
needs of our partners as they move their therapeutic programs
through clinical development to approval and commercialization.
Building out these advanced capabilities will also enable the
Company to continue our expansion into new research areas and
applications for use of our technology.
“We believe strongly in creating an environment
where employees know that we are in this together and that their
efforts, individually and as a team, are contributing to MaxCyte’s
success and ultimately, delivering new therapeutics to patients. We
want all of our employees to feel valued and to be empowered to
make a difference,” said Jill Mayer,
Vice President of Talent and Teamwork at
MaxCyte.
According to CBRE’s I-270 Biotech Corridor: 2021
Year-End Report, Maryland is the fifth largest biotech hub in the
US and is experiencing significant and rapid growth due to the
influx of public and private sector funding. Maryland ranked first
in the Milken Institute’s 2020 State Technology and Science Index
technology and science workforce subindex and second in the
research and development sub-index, with the highest levels of
federal government and academic funding for R&D of any state.
Rockville is at the center of the I-270 Biotech Corridor and its
Economic Development partnership boasts more than 10,000 bio health
workers in the private sector, 49,000 in federal government
agencies, and 150+ life sciences companies with a Rockville
address, not to mention its close proximity to the National
Institutes of Health, US Food and Drug Administration, and other
Federal and academic institutions.
“We are excited for the future and see our move
to this new facility as a milestone in MaxCyte’s growth and the
expansion of the region’s biotech community,” said Mr. Doerfler.
“We are here to help save lives. That’s what drives us to innovate
and make our partners successful.”
About MaxCyteMaxCyte is a
leading commercial cell-engineering company focused on providing
enabling platform technologies to advance innovative cell-based
research as well as next-generation cell therapeutic discovery,
development and commercialization. Over the past 20 years, we have
developed and commercialized our proprietary Flow Electroporation®
platform, which facilitates complex engineering of a wide variety
of cells. Our ExPERT™ platform, which is based on our Flow
Electroporation technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: three instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. Learn more at
maxcyte.com and follow us on Twitter and LinkedIn.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400jr@maxcyte.com
US Media
RelationsSeismic Collaborative, A Spectrum Science
CompanyValerie Enes+1
408-497-8568valerie@teamseismic.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium
Strategic CommunicationsMary-Jane Elliott / Chris Welsh+44
(0)203 709 5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024